Monday, 11 May 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 11 May 2026
News

'Slow to respond' CSL nosedives

Posted 11 May 2026 PM

CSL has seen its market cap nosedive this morning as it cut its financial forecast for the financial year, to the lowest share price since December 2016.

Interim CEO Gordon Naylor, who took the helm in February, gave a 90 Day Review and Financial Update to investors this morning, joined by Chief Financial Officer Ken Lim. The news was grim, prompting a 22 per cent fall in share price compared to the closing on Friday, although it recovered to be down around 17 per cent for the day, just below $100.

To see the whole article, please login

Popular

$135M market under threat
Industry's 'Most Influential' named
Aussie class action targets pharma
PBAC July Agenda blows out to 58
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home